Logo image of PHVS

PHARVARIS NV (PHVS) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:PHVS - NL00150005Y4 - Common Stock

25.04 USD
+0.99 (+4.12%)
Last: 1/7/2026, 8:00:01 PM
25 USD
-0.04 (-0.16%)
After Hours: 1/7/2026, 8:00:01 PM
Fundamental Rating

2

PHVS gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 191 industry peers in the Pharmaceuticals industry. The financial health of PHVS is average, but there are quite some concerns on its profitability. PHVS is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year PHVS has reported negative net income.
In the past year PHVS has reported a negative cash flow from operations.
PHVS had negative earnings in each of the past 5 years.
In the past 5 years PHVS always reported negative operating cash flow.
PHVS Yearly Net Income VS EBIT VS OCF VS FCFPHVS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -50M -100M

1.2 Ratios

Looking at the Return On Assets, with a value of -48.31%, PHVS is in line with its industry, outperforming 40.31% of the companies in the same industry.
PHVS's Return On Equity of -52.43% is in line compared to the rest of the industry. PHVS outperforms 52.36% of its industry peers.
Industry RankSector Rank
ROA -48.31%
ROE -52.43%
ROIC N/A
ROA(3y)-38.96%
ROA(5y)-32.55%
ROE(3y)-42.51%
ROE(5y)-35.1%
ROIC(3y)N/A
ROIC(5y)N/A
PHVS Yearly ROA, ROE, ROICPHVS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

PHVS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PHVS Yearly Profit, Operating, Gross MarginsPHVS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024

More info and screens

6

2. Health

2.1 Basic Checks

The number of shares outstanding for PHVS has been increased compared to 1 year ago.
The number of shares outstanding for PHVS has been increased compared to 5 years ago.
Compared to 1 year ago, PHVS has a worse debt to assets ratio.
PHVS Yearly Shares OutstandingPHVS Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
PHVS Yearly Total Debt VS Total AssetsPHVS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

An Altman-Z score of 26.98 indicates that PHVS is not in any danger for bankruptcy at the moment.
PHVS has a better Altman-Z score (26.98) than 90.58% of its industry peers.
A Debt/Equity ratio of 0.00 indicates that PHVS is not too dependend on debt financing.
With a decent Debt to Equity ratio value of 0.00, PHVS is doing good in the industry, outperforming 61.26% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 26.98
ROIC/WACCN/A
WACCN/A
PHVS Yearly LT Debt VS Equity VS FCFPHVS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

A Current Ratio of 12.86 indicates that PHVS has no problem at all paying its short term obligations.
The Current ratio of PHVS (12.86) is better than 80.63% of its industry peers.
A Quick Ratio of 12.86 indicates that PHVS has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 12.86, PHVS belongs to the top of the industry, outperforming 80.63% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 12.86
Quick Ratio 12.86
PHVS Yearly Current Assets VS Current LiabilitesPHVS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for PHVS have decreased strongly by -12.19% in the last year.
EPS 1Y (TTM)-12.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%22.47%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, PHVS will show a very strong growth in Earnings Per Share. The EPS will grow by 20.28% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-16.26%
EPS Next 2Y-6.42%
EPS Next 3Y2.7%
EPS Next 5Y20.28%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PHVS Yearly Revenue VS EstimatesPHVS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
PHVS Yearly EPS VS EstimatesPHVS Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 6 8 10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

PHVS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PHVS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PHVS Price Earnings VS Forward Price EarningsPHVS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PHVS Per share dataPHVS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-6.42%
EPS Next 3Y2.7%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for PHVS!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

PHARVARIS NV

NASDAQ:PHVS (1/7/2026, 8:00:01 PM)

After market: 25 -0.04 (-0.16%)

25.04

+0.99 (+4.12%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-12 2025-11-12/bmo
Earnings (Next)04-06 2026-04-06/amc
Inst Owners63.01%
Inst Owner Change0%
Ins Owners5.32%
Ins Owner ChangeN/A
Market Cap1.60B
Revenue(TTM)N/A
Net Income(TTM)-163.72M
Analysts86.67
Price Target46.84 (87.06%)
Short Float %1.62%
Short Ratio1.77
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)3.35%
Min EPS beat(2)-5.58%
Max EPS beat(2)12.28%
EPS beat(4)2
Avg EPS beat(4)2.63%
Min EPS beat(4)-9.19%
Max EPS beat(4)12.99%
EPS beat(8)4
Avg EPS beat(8)-5.11%
EPS beat(12)7
Avg EPS beat(12)-7.9%
EPS beat(16)11
Avg EPS beat(16)5.73%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)23.82%
PT rev (3m)38%
EPS NQ rev (1m)0%
EPS NQ rev (3m)4.16%
EPS NY rev (1m)-2.12%
EPS NY rev (3m)-0.43%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 4.37
P/tB 4.37
EV/EBITDA N/A
EPS(TTM)-3.43
EYN/A
EPS(NY)-3.3
Fwd EYN/A
FCF(TTM)-2.47
FCFYN/A
OCF(TTM)-2.46
OCFYN/A
SpS0
BVpS5.73
TBVpS5.73
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -48.31%
ROE -52.43%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-38.96%
ROA(5y)-32.55%
ROE(3y)-42.51%
ROE(5y)-35.1%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 80.1%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 12.86
Quick Ratio 12.86
Altman-Z 26.98
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)104.84%
Cap/Depr(5y)175.41%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-12.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%22.47%
EPS Next Y-16.26%
EPS Next 2Y-6.42%
EPS Next 3Y2.7%
EPS Next 5Y20.28%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-30.94%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-17.26%
EBIT Next 3Y-6.08%
EBIT Next 5Y21.07%
FCF growth 1Y-49.78%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-49.55%
OCF growth 3YN/A
OCF growth 5YN/A

PHARVARIS NV / PHVS FAQ

Can you provide the ChartMill fundamental rating for PHARVARIS NV?

ChartMill assigns a fundamental rating of 2 / 10 to PHVS.


What is the valuation status for PHVS stock?

ChartMill assigns a valuation rating of 0 / 10 to PHARVARIS NV (PHVS). This can be considered as Overvalued.


Can you provide the profitability details for PHARVARIS NV?

PHARVARIS NV (PHVS) has a profitability rating of 1 / 10.